Urogen Pharma (URGN) Projected to Post Quarterly Earnings on Thursday

Urogen Pharma (NASDAQ:URGN - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect Urogen Pharma to post earnings of ($0.85) per share and revenue of $23.06 million for the quarter.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). Urogen Pharma had a negative net margin of 150.68% and a negative return on equity of 97,487.15%. The firm had revenue of $20.25 million for the quarter, compared to the consensus estimate of $22.71 million. On average, analysts expect Urogen Pharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Urogen Pharma Stock Up 1.8%

Shares of NASDAQ URGN traded up $0.34 during midday trading on Friday, reaching $19.40. 1,007,990 shares of the company's stock traded hands, compared to its average volume of 1,235,309. The company has a market cap of $896.28 million, a price-to-earnings ratio of -6.10 and a beta of 1.12. The stock's 50 day simple moving average is $12.21 and its 200-day simple moving average is $10.96. Urogen Pharma has a one year low of $3.42 and a one year high of $19.74.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Urogen Pharma in a research report on Tuesday, July 8th. Scotiabank restated an "outperform" rating on shares of Urogen Pharma in a research note on Friday, June 13th. D. Boral Capital reissued a "buy" rating and issued a $25.00 price target on shares of Urogen Pharma in a research note on Monday, July 7th. The Goldman Sachs Group set a $16.00 price objective on Urogen Pharma and gave the stock a "neutral" rating in a research note on Friday, June 13th. Finally, Oppenheimer set a $31.00 price target on Urogen Pharma and gave the stock a "buy" rating in a research note on Friday, June 13th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $32.86.

Insider Buying and Selling

In other news, General Counsel Jason Drew Smith sold 7,522 shares of Urogen Pharma stock in a transaction on Monday, July 28th. The shares were sold at an average price of $19.14, for a total value of $143,971.08. Following the transaction, the general counsel directly owned 41,492 shares of the company's stock, valued at $794,156.88. The trade was a 15.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mark Schoenberg sold 5,149 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $19.14, for a total transaction of $98,551.86. Following the sale, the insider owned 158,229 shares of the company's stock, valued at approximately $3,028,503.06. This represents a 3.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 17,833 shares of company stock worth $280,567 over the last three months. Insiders own 5.10% of the company's stock.

Institutional Trading of Urogen Pharma

Hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC grew its holdings in shares of Urogen Pharma by 347.5% in the 1st quarter. AQR Capital Management LLC now owns 114,066 shares of the company's stock worth $1,262,000 after acquiring an additional 88,577 shares during the period. Jane Street Group LLC raised its holdings in shares of Urogen Pharma by 94.3% in the first quarter. Jane Street Group LLC now owns 51,177 shares of the company's stock worth $566,000 after acquiring an additional 24,839 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Urogen Pharma by 7.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company's stock valued at $258,000 after acquiring an additional 1,653 shares in the last quarter. 91.29% of the stock is owned by institutional investors and hedge funds.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.